ATE435660T1 - Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen - Google Patents

Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen

Info

Publication number
ATE435660T1
ATE435660T1 AT05850393T AT05850393T ATE435660T1 AT E435660 T1 ATE435660 T1 AT E435660T1 AT 05850393 T AT05850393 T AT 05850393T AT 05850393 T AT05850393 T AT 05850393T AT E435660 T1 ATE435660 T1 AT E435660T1
Authority
AT
Austria
Prior art keywords
tumor antigens
polypeptide consisting
immunogenic polypeptide
polypeptide
optimized
Prior art date
Application number
AT05850393T
Other languages
English (en)
Inventor
Konstantinos Kosmatopoulos
Sebastien Cornet
Original Assignee
Vaxon Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxon Biotech filed Critical Vaxon Biotech
Application granted granted Critical
Publication of ATE435660T1 publication Critical patent/ATE435660T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
AT05850393T 2005-12-23 2005-12-23 Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen ATE435660T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2005/014212 WO2007073768A1 (en) 2005-12-23 2005-12-23 Immunogenic polypeptide composed of tumor antigen-derived optimized cryptic peptides, and uses thereof

Publications (1)

Publication Number Publication Date
ATE435660T1 true ATE435660T1 (de) 2009-07-15

Family

ID=36000393

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05850393T ATE435660T1 (de) 2005-12-23 2005-12-23 Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen

Country Status (12)

Country Link
US (1) US7973128B2 (de)
EP (1) EP1962889B1 (de)
JP (1) JP4929290B2 (de)
CN (1) CN101370513B (de)
AT (1) ATE435660T1 (de)
CA (1) CA2634480C (de)
DE (1) DE602005015368D1 (de)
DK (1) DK1962889T3 (de)
ES (1) ES2330658T3 (de)
PL (1) PL1962889T3 (de)
PT (1) PT1962889E (de)
WO (1) WO2007073768A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012523379A (ja) * 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
CN102153658A (zh) * 2011-01-19 2011-08-17 上海科医联创生物科技有限公司 肿瘤抗原、dc肿瘤疫苗及其制备方法
EP2886127A1 (de) * 2013-12-18 2015-06-24 Vaxon Biotech Verfahren zur Emulgierung eines Triepitoppeptids mit Montanid und Kits zu seiner Durchführung
EP2977059A1 (de) * 2014-07-22 2016-01-27 Vaxon Biotech Immunogenes Polypeptid aus HLA-B7-beschränkten, tumorantigenabgeleiteten, optimierten kryptischen Peptiden und Verwendungen davon
CN104926944B (zh) * 2015-05-22 2018-04-13 北京康爱瑞浩生物科技股份有限公司空港分公司 多靶点复合抗原负载cd8+细胞毒性t淋巴细胞的制备方法及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041787A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
AU5810201A (en) 2000-05-10 2001-11-20 Aventis Pasteur Immunogenic polypeptides encoded by mage minigenes and uses thereof
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie

Also Published As

Publication number Publication date
CN101370513B (zh) 2013-04-03
PL1962889T3 (pl) 2010-03-31
EP1962889A1 (de) 2008-09-03
ES2330658T3 (es) 2009-12-14
DK1962889T3 (da) 2009-11-02
US20090130133A1 (en) 2009-05-21
PT1962889E (pt) 2009-10-14
JP2009520472A (ja) 2009-05-28
EP1962889B1 (de) 2009-07-08
JP4929290B2 (ja) 2012-05-09
DE602005015368D1 (de) 2009-08-20
WO2007073768A1 (en) 2007-07-05
CA2634480A1 (en) 2007-07-05
US7973128B2 (en) 2011-07-05
CN101370513A (zh) 2009-02-18
CA2634480C (en) 2013-10-15

Similar Documents

Publication Publication Date Title
HK1134507A1 (en) Peptide vaccines for cancers expressing tumor-associated antigens
HK1220709A1 (zh) 混雜地結合於人類白細胞抗原 類分子的腫瘤相關肽
JP2014507146A5 (de)
JP2008543314A5 (de)
EP2562183A8 (de) Neuartige immunogenetische Epitope zur Immuntherapie
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
JP2007516696A5 (de)
ATE435660T1 (de) Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen
AR053372A1 (es) Proteinas inmunologicas de lawsonia intracellularis
MX2009007261A (es) Vacuna de peptido foxp3.
CY1112867T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
NZ598605A (en) Vaccine against african horse sickness virus
WO2005007673A3 (en) Immunogenic peptides
UA102274C2 (ru) Эпитопный пептид rab6kifl/kif20a и вакцины, которые его содержат
TW201008576A (en) New fusion proteins and their use for the preparation of vaccines against hepatitis C
MX2010010025A (es) Proteina de fusion con direccionamiento de antigenos vacunales a celulas presentadoras de antigeno y sus aplicaciones.
PH12018502430A1 (en) Vaccines
MX2013004417A (es) Peptidos wdhd1 y vacunas que los incluyen.
RU2021112253A (ru) Вирусоподобные частицы cmv, модифицированные путем слияния
WO2009149094A3 (en) Cytotoxic t cell defined egfr peptide and an optimized derivative peptide
CY1114720T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
TH88495B (th) วัคซีนชนิดใหม่สำหรับปรสิตทางทะเล

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1962889

Country of ref document: EP